Glenmark Pharmaceuticals Limited — Q3 FY26
Glenmark delivered a strong Q3 with consolidated revenue of ₹3,962 crore, up 15.1% YoY, driven by broad-based growth across markets and currency tailwinds.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
India business run-rate of ₹1,150-1,200 crore from Q3 FY26
Management expects India formulation sales to normalize to ₹1,150-1,200 crore per quarter starting Q3 FY26, with FY27 revenue exceeding ₹4,800 crore.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
EBITDA margin of 23% immediately, targeting 25%+
Post balance sheet cleanup, EBITDA margin will trend to 23% and strengthen to over 25% in coming years.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1